OxSyBio Raises £1 Million to Develop Synthetic 3D Printed Tissues For Organ and Skin Repairs

Share this Article

The 3D bioprinting space is certainly beginning to get the attention of investors. There are now several companies with the funding needed to develop techniques which could one day lead to a major breakthrough in regenerative medicine.ox-1 

Today, Isis Innovation, the University of Oxford’s research commercialisation company, announced that OxSyBio Ltd., a spin-out from the University, has raised £1 million from IP Group plc to develop their proprietary 3D droplet printing technology. Professor Hagan Bayley’s group at the University’s Department of Chemistry are the ones who came up with this approach to 3d bioprinting. They used thousands of tiny droplets, coated with a film that mimics the external membrane of an actual living cell. The team then studded the membranes with protein pores, making them act just like simplified cells.

The droplets, which OxSyBio prints, can transmit electrical pulses, like the ones that are used by living cells, to communicate in the human nervous system.

“We also aim to integrate printed tissue-like materials with living tissues, and to print materials that themselves contain living cells. Our long-term goal is to develop a synthetic-tissue printer that a surgeon can use in the operating theatre. In ten years’ time, the use of pieces of synthetic tissue will be commonplace. The fabrication of complex synthetic organs is a more distant prospect. I ox-2am delighted to be working with Isis and IP Group to accelerate the development of our new company, OxSyBio. Our goal is to establish ourselves at the frontline of regenerative medicine,” stated Professor Hagan Bayley.

Regenerative medicine is certainly a field that will garner a lot of investor interest over the coming years, as the prospects of 3D printing organs, patches, and other living tissue increases because of natural technological progress.

Alan Aubrey, Chief Executive Officer of IP Group, said: “Synthetic biology and regenerative medicine will be central to the development of healthcare in the 21st century and IP Group is pleased to support OxSyBio as it seeks to develop products that will help to realize the potential of these exciting and growing areas.”

OxSyBio was formed just last month and is based in London England. You can participate in the discussion about OxSyBio, and their 3D droplet bioprinting technology at 3DPrintBoard.

ox-feat

Share this Article


Recent News

3D Printing in India: Slow Adoption & What the Future Holds

Nexa3D Acquires NXT Factory, Introduces Eco-Friendly 3D Printing Washing Solvent



Categories

3D Design

3D Printed Art

3D printed automobiles

3D Printed Food


You May Also Like

3D Printing Webinar and Virtual Event Roundup, August 2, 2020

It’s another busy week in the 3D printing industry that’s packed full of webinars and virtual events, ranging in topics from medical materials and flexible electronics to polypropylene and market...

T3D Announces New LCD-Based High-Speed 3D Printing System

Taiwan 3D Tech, also known as T3D, is a startup spin-off from the National Taiwan University of Science and Technology (NTUST). Headquartered in Taipei, the company was officially founded in...

Fraunhofer and RMIT Form Cross-Continental 3D Printing Partnership

While RMIT University is known for specializing in technology and design, Fraunhofer Institute for Material and Beam Technology IWS is a force to contend with, known as a leading applied...

3D Printing News Briefs, July 25, 2020: MakerBot, ANSYS, Sintavia, Nexa3D & Henkel

We’re all business in today’s 3D Printing News Briefs! MakerBot has a new distribution partner, and ANSYS is launching a new product. Sintavia has acquired an additional Arcam 3D printer...


Shop

View our broad assortment of in house and third party products.